AngioDynamics Q4 FY26 adjusted loss per share widens to $0.07; net sales rise 8% to $86.6 million - ANGO News | RalliesAngioDynamics Q4 FY26 adjusted loss per share widens to $0.07; net sales rise 8% to $86.6 million
A
ANGO• Fiscal 2027 outlook
- Guided fiscal 2027 net sales at $336 million-$341 million; expects Med Tech net sales growth of 12%-15%.
Fourth-quarter and full-year results
- AngioDynamics posted fiscal Q4 net sales of $86.6 million, up 8.0% year over year; GAAP loss per share widened to $0.27.
- GAAP gross margin rose 1.3 percentage points to 54.0%.
- Full-year net sales climbed 9.4% to $320.2 million; GAAP loss per share widened to $0.88.
- Adjusted EBITDA improved to $13.2 million from $7.6 million; cash totaled $53.9 million at year-end.
•
